Biovitrum Initiates Phase II Clinical Trial of Novel Pain Treatment
Biovitrum examines a novel method for treating pain in a phase II clinical trial. The treatment aims at neuropathic pain, which is a chronic form of pain resulting from nerve injuries. Contrary to current treatments that act in the brain, Biovitrum’s substance is expected to act peripherally, directly in the injured nerve. There is a very large unmet medical need in this area. The market is estimated to approximately SEK 18 billion. The study is expected to include up to 300 patients and results are expected during the first half of 2008.
The drug candidate presently tested is a substance that activates a protein (adenosine receptor 2A) that, among other things, is responsible for reducing inflammations. The substance is expected to have a pain-alleviating effect by reducing inflammation directly in the damaged nerve whereas available treatments mainly are represented by drugs acting in the brain. The efficacy of these drugs is limited and the risk is high for side effects such as dizziness, nausea and somnolence. As Biovitrum’s substance acts at the site of injury peripherally in the body, the risk is reduced for this type of side effects related to the central nervous system. This therefore represents a novel treatment with both reduced risk of side effects and the potential for analgesic as well as anti-inflammatory effects.
“Yet another project in our portfolio with a new and safer treatment is now advancing into clinical phase II trials. Neuropathic pain is an indication for which there is a large unmet need and huge market potential, where we will seek a partnership for late-stage development and marketing. We hope our efforts will lead to a safe and effective drug that will improve the situation for many patients who suffer from chronic pain,” says Biovitrum’s CEO Mats Pettersson.
Biovitrum currently has seven projects in clinical trials and an option of an eight;
three in phase II and four in phase I within mainly the areas of inflammation and hematological and metabolic disorders. Results from ongoing clinical trials are expected according to previously communicated time plan. However, due to a delay in patient recruitment the results from phase II in the glaucoma project 5-HT2A are expected during second half of 2007, instead of mid 2007 as previously announced.
For more information, contact:
Biovitrum AB (publ)
Mats Pettersson, CEO
Phone: +46 8 697 20 00
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.